Sell Alert: Nikita Shah Cashes Out $2.56M In Amneal Pharmaceuticals Stockbenzinga_article·Aug 14 at 10:04 AMAMRX-0.73%
Amneal EVP, Chief Legal Officer Jason B. Daly sells USD 3.77 million in common sharesPUBT·Aug 13 at 03:27 PMAMRX-0.73%
Amneal reprices term loan, cuts interest margin 50 bps on USD 2.08 billion facilityPUBT·Aug 3 at 03:40 PMAMRX-0.73%
Did Strong Q2 Results and Higher 2026 Revenue Guidance Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative?Simplywall·Aug 3 at 06:23 AMAMRX-0.73%
Amneal Pharmaceuticals, Inc. $AMRX Shares Acquired by Bank of New York Mellon CorpMarket Beat·Aug 2 at 02:36 AMAMRX-0.73%
Dimensional Fund Advisors LP Raises Holdings in Amneal Pharmaceuticals, Inc. $AMRXMarket Beat·Aug 1 at 03:00 AMAMRX-0.73%
Amneal Pharmaceuticals (AMRX) Stock Asks If Profit Momentum Can EndureSimplywall·Jul 31 at 06:18 PMAMRX-0.73%
Amneal Pharmaceuticals held special shareholder meeting on Kashiv BioSciences dealPUBT·Jul 31 at 03:10 PMAMRX-0.73%
AMRX: Acquisition of Kashiv BioSciences and related share issuance proposals were approved by stockholdersQuartr·Jul 31 at 09:01 AMAMRX-0.73%
AMRX: Q2 revenue and profit surged, outlook raised, and biosimilar expansion accelerates with KashivQuartr·Jul 30 at 09:21 AMAMRX-0.73%
Amneal Q2 FY26 GAAP net income more than doubles to $58 million; revenue rises 10% to $796 millionPUBT·Jul 30 at 05:09 AMAMRX-0.73%
